Literature DB >> 15086908

Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum.

M Barry Stokes1, Glen S Markowitz, Julie Lin, Anthony M Valeri, Vivette D D'Agati.   

Abstract

BACKGROUND: The glomerular tip lesion (GTL) is a distinctive but controversial histopathologic lesion occurring in patients with idiopathic nephrotic syndrome. The relationship of GTL to minimal change disease (MCD) and idiopathic focal segmental glomerulosclerosis (FSGS) has been disputed.
METHODS: In order to define the clinical features and natural history of GTL, we retrospectively reviewed the presenting clinical features, biopsy findings and outcome of 47 cases. Presenting clinical features of GTL were compared to those of controls with MCD (N= 61) or idiopathic FSGS (N= 50).
RESULTS: The cohort of GTL consisted of 45 adults and two children (mean age 47.5 years; range 12 to 79 years), including 76.6% Caucasians and 53% males. At presentation, 93.6% of patients had edema, 89.1% had nephrotic syndrome (mean urine protein 8.31 g, mean serum albumin 2.27 g/dL, and mean cholesterol 340.6 mg/dL), and 34.8% had renal insufficiency. Mean time from onset of renal disease to biopsy was 2.4 months. At biopsy, glomerular segmental lesions included GTL alone in 26%, GTL and peripheral lesions in 6%, GTL and indeterminate lesions in 36%, and GTL with peripheral and indeterminate lesions in 32%. No initial biopsy contained perihilar sclerosis and most (81%) segmental lesions were cellular. Follow-up data were available in 29 patients, of whom 21 received steroids alone and eight received sequential therapy with steroids and a cytotoxic agent. At a mean follow-up of 21.5 months, 58.6% of patients achieved complete remission of nephrotic syndrome, 13.8% had partial remission, and 27.6% had persistent nephrotic proteinuria. Only one patient progressed to end-stage renal disease (ESRD). Predictors of nonremission included severity of proteinuria at presentation and % peripheral lesions. When compared to controls with MCD and idiopathic FSGS, GTL more closely resembled MCD with respect to high incidence of nephrotic syndrome (P < 0.001), severity of proteinuria (P < 0.05), short duration from onset to biopsy (P < 0.001), and absence of chronic tubulointerstitial disease (P < 0.0054).
CONCLUSION: Within the MCD/FSGS spectrum, GTL is a distinctive and prognostically favorable clinical-pathologic entity whose presenting features and outcome more closely approximate those of MCD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15086908     DOI: 10.1111/j.1523-1755.2004.00563.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  29 in total

Review 1.  Glomerular diseases: FSGS.

Authors:  Bhadran Bose; Daniel Cattran
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 8.237

Review 2.  Protecting Podocytes: A Key Target for Therapy of Focal Segmental Glomerulosclerosis.

Authors:  Kirk N Campbell; James A Tumlin
Journal:  Am J Nephrol       Date:  2018-05-31       Impact factor: 3.754

3.  Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS.

Authors:  Louis-Philippe Laurin; Adil M Gasim; Caroline J Poulton; Susan L Hogan; J Charles Jennette; Ronald J Falk; Bethany J Foster; Patrick H Nachman
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-16       Impact factor: 8.237

4.  A spectrum of morphologic lesions of focal segmental glomerulosclerosis by Columbia criteria in human immunodeficiency virus infection.

Authors:  Shane M Meehan; Lisa Kim; Anthony Chang
Journal:  Virchows Arch       Date:  2012-03-03       Impact factor: 4.064

Review 5.  Novel biomarkers in glomerular disease.

Authors:  Yasar Caliskan; Krzysztof Kiryluk
Journal:  Adv Chronic Kidney Dis       Date:  2014-03       Impact factor: 3.620

6.  Predictive factors of chronic kidney disease in primary focal segmental glomerulosclerosis.

Authors:  Marcelo M Abrantes; Luis Sergio B Cardoso; Eleonora M Lima; José M Penido Silva; José S Diniz; Eduardo A Bambirra; Eduardo A Oliveira
Journal:  Pediatr Nephrol       Date:  2006-05-30       Impact factor: 3.714

Review 7.  Problems with 'focal segmental glomerulosclerosis'.

Authors:  Alexander J Howie
Journal:  Pediatr Nephrol       Date:  2010-12-02       Impact factor: 3.714

8.  Predictors of long-term outcome of children with idiopathic focal segmental glomerulosclerosis.

Authors:  Asiri S Abeyagunawardena; Neil J Sebire; R Anthony Risdon; Michael J Dillon; Lesley Rees; William Van't Hoff; Pallegoda V Kumarasiri; Richard S Trompeter
Journal:  Pediatr Nephrol       Date:  2006-12-05       Impact factor: 3.714

9.  Association of histologic variants in FSGS clinical trial with presenting features and outcomes.

Authors:  Vivette D D'Agati; Joan M Alster; J Charles Jennette; David B Thomas; James Pullman; Daniel A Savino; Arthur H Cohen; Debbie S Gipson; Jennifer J Gassman; Milena K Radeva; Marva M Moxey-Mims; Aaron L Friedman; Frederick J Kaskel; Howard Trachtman; Charles E Alpers; Agnes B Fogo; Tom H Greene; Cynthia C Nast
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-06       Impact factor: 8.237

Review 10.  Corticosteroid-resistant nephrotic syndrome with focal and segmental glomerulosclerosis : an update of treatment options for children.

Authors:  Jochen H H Ehrich; Lars Pape; Mario Schiffer
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.